CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback